What does this research mean for the field?

In patients with JAK2 V617F-positive erythrocytosis, a diagnostic variant allele frequency (VAF) greater than 50% is independently associated with an increased risk of subsequent thrombosis. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To examine associations between diagnostic JAK2 V617F variant allele frequency tiers and clinical, laboratory, bone marrow, and thrombotic outcomes in JAK2 V617F-positive erythrocytosis.

September 5, 2026International Journal of Laboratory Hematology

Clinical and Laboratory Associations of JAK2 V617F Variant Allele Frequency in Patients With JAK2 V617F ‐Positive Erythrocytosis: A Single‐Centre Retrospective Analysis

View Full Paper

Ask AI

Bookmark

Authors

TCTahir Alper CinliIstanbul Metropolitan Municipality ÇÇÇisem ÇınarEducation Training And Research

Discussion

Member takes

Implication

Retrospective cohort study finds higher JAK2 V617F variant allele frequency increases thrombosis risk in patients with erythrocytosis, highlighting allele burden as a key prognostic marker.

Key Points

To examine associations between diagnostic JAK2 V617F variant allele frequency tiers and clinical, laboratory, bone marrow, and thrombotic outcomes in JAK2 V617F-positive erythrocytosis.
Single-centre retrospective cohort study including 174 adult patients with JAK2 V617F-positive erythrocytosis.
Stratified patients by diagnostic variant allele frequency (VAF) into low (< 5%; n = 62), intermediate (5%–50%; n = 81), and high (> 50%; n = 31) categories.
Compared clinical characteristics, laboratory values, and bone marrow findings, and used multivariable logistic regression to evaluate factors associated with incident thrombosis.
Thrombosis rates increased across low, intermediate, and high VAF groups (12.9% vs. 22.2% vs. 48.4%; p = 0.001), alongside rising rates of splenomegaly (25.8% vs. 53.1% vs. 64.5%; p < 0.001) and myelofibrosis transformation (1.6% vs. 13.6% vs. 20.0%; p = 0.011).
A diagnostic VAF > 50% was independently associated with subsequent thrombosis (OR: 3.35; 95% CI: 1.06–10.58; p = 0.039), as was platelet count (OR: 9.92; 95% CI: 1.52–64.63; p = 0.016).
Median serum erythropoietin decreased across ascending VAF groups (8.0 vs. 3.1 vs. 2.2 mIU/mL; p < 0.001), and polycythemia vera-supportive bone marrow morphology was present in 50.0%, 93.5%, and 100% of biopsied patients across respective tiers.

Cite This Study

Cinli et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4606b95aff0620ec174 https://doi.org/10.1111/ijlh.70242

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study finds higher JAK2 V617F variant allele frequency increases thrombosis risk in patients with erythrocytosis, highlighting allele burden as a key prognostic marker.

Clinical and Laboratory Associations of JAK2 V617F Variant Allele Frequency in Patients With JAK2 V617F ‐Positive Erythrocytosis: A Single‐Centre Retrospective Analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical and Laboratory Associations of JAK2 V617F Variant Allele Frequency in Patients With JAK2 V617F ‐Positive Erythrocytosis: A Single‐Centre Retrospective Analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider